Phase I Study to Investigate the Drug Interaction After Oral Administration of Tamsulosin and SK3530

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

To assess the pharamcodynamic effects of coadministrated SK3530(PDE5 inhibitor) and tamsulosin, phase I study in healthy volunteers was designed.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: SK Chemicals Co., Ltd.; SK Chemicals Co.,Ltd.
• Treatments: Tamsulosin

Criteria

Inclusion Criteria:

• ages 20 to 50

• body weight of IBM±20%

Exclusion Criteria:

• cardiovascular disease

• color-blindness or weakness

• hypotension, hypertension, orthostatic hypertension

• abmormal QTc (>430 ms)